Holen Sie sich die Stockscreener-App
9.16
2.93%
0.30
Schlusskurs vom Vortag:
$8.86
Offen:
$8.92
24-Stunden-Volumen:
120.87K
Relative Volume:
0.10
Marktkapitalisierung:
$730.90M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-106.81M
KGV:
-2.766
EPS:
-3.3117
Netto-Cashflow:
$-8.40M
1W Leistung:
+8.57%
1M Leistung:
+35.92%
6M Leistung:
-21.31%
1J Leistung:
-39.08%
1-Tages-Spanne:
$8.86
$9.15
1-Wochen-Bereich:
$8.31
$9.15
52-Wochen-Spanne:
$5.1501
$16.81
Immunome Inc Stock (IMNM) Company Profile
Firmenname
Immunome Inc
Sektor
Branche
Telefon
610-321-3700
Adresse
18702 N. CREEK PARKWAY, BOTHELL
Vergleichen Sie IMNM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMNM
Immunome Inc
|
9.1309 | 730.90M | 0 | -106.81M | -8.40M | -3.3117 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.34 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.65 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
651.56 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
260.64 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
256.18 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Immunome Inc Stock (IMNM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-02 | Eingeleitet | Lake Street | Buy |
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-31 | Eingeleitet | Piper Sandler | Overweight |
| 2024-04-30 | Eingeleitet | JP Morgan | Overweight |
| 2024-04-15 | Eingeleitet | Guggenheim | Buy |
| 2024-01-29 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-19 | Eingeleitet | Wedbush | Outperform |
| 2021-10-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
Alle ansehen
Immunome Inc Aktie (IMNM) Neueste Nachrichten
(IMNM) Investment Analysis and Advice - news.stocktradersdaily.com
Taking on analysts’ expectations and winning: Immunome Inc (IMNM) - Sete News
Immunome Inc [IMNM] stock for 60,684 USD was acquired by BIENAIME JEAN JACQUES - knoxdaily.com
Legal & General Group Plc Sells 8,796 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome (IMNM) Trades at Significant Discount, Piper Sandler An - GuruFocus
Piper says SpringWorks deal suggests Immunome’s varegacestat ‘undervalued’ - TipRanks
Was there any good news for Immunome Inc (IMNM) stock in the last session? - uspostnews.com
Investing in Immunome Inc (IMNM): What You Must Know - knoxdaily.com
A company insider recently bought 7,800 shares of Immunome Inc [IMNM]. Should You Buy? - knoxdaily.com
Financial Snapshot: Analyzing Immunome Inc (IMNM)’s Key Ratio Metrics - DWinneX
Immunome Inc (IMNM)’s stock price in review: A technical analysis - uspostnews.com
Geode Capital Management LLC Has $13.05 Million Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome: Transformed Pipeline Offers Multiple Catalysts (NASDAQ:IMNM) - Seeking Alpha
JPMorgan Chase & Co. Acquires 624,045 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
How To Trade (IMNM) - news.stocktradersdaily.com
Wellington Management Group LLP Raises Position in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Vanguard Group Inc. Sells 128,130 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Announces Management Changes - marketscreener.com
KLP Kapitalforvaltning AS Invests $75,000 in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Corebridge Financial Inc. Sells 1,929 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Commonwealth Equity Services LLC Buys Shares of 19,017 Immunome, Inc. (NASDAQ:IMNM) - Defense World
Raymond James Financial Inc. Acquires Shares of 25,817 Immunome, Inc. (NASDAQ:IMNM) - Defense World
Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? - Yahoo Finance
Brokerages Set Immunome, Inc. (NASDAQ:IMNM) PT at $25.14 - Defense World
Immunome stock hits 52-week low at $5.5 amid market challenges - Investing.com
Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference - BioSpace
Immunome's Latest Cancer Therapy Progress: Key Investor Presentation Coming to Needham Conference - Stock Titan
Lake Street Capital Begins Coverage on Immunome (NASDAQ:IMNM) - Defense World
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Joplin Globe
Teacher Retirement System of Texas Purchases New Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Clay Siegall Bought 20% More Shares In Immunome - simplywall.st
Corient Private Wealth LLC Sells 12,149 Shares of Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome Inc IMNM’s stock price falss traction on Tuesday - uspostnews.com
Immunome stock hits 52-week low at $6.94 amid market challenges - Investing.com Australia
Immunome stock hits 52-week low at $6.94 amid market challenges By Investing.com - Investing.com South Africa
Immunome (NASDAQ:IMNM) Stock Price Up 4.4% After Insider Buying Activity - Defense World
Immunome (IMNM) Stock Climbs as Executives Increase Holdings - GuruFocus
Immunome director Jean Jacques Bienaime acquires $60,684 in stock - Investing.com
Immunome director Jean Jacques Bienaime acquires $60,684 in stock By Investing.com - Investing.com South Africa
Immunome CEO Clay Siegall buys $999k in stock By Investing.com - Investing.com Canada
Immunome CEO Clay Siegall buys $999k in stock - Investing.com India
Immunome stock rises after insider purchase (IMNM:NASDAQ) - Seeking Alpha
Immunome stock rises after insider purchase - MSN
Immunome director Jean Jacques Bienaime purchases $57,470 in stock By Investing.com - Investing.com Canada
Charles Schwab Investment Management Inc. Increases Holdings in Immunome, Inc. (NASDAQ:IMNM) - Defense World
Immunome CTO Philip Tsai purchases $103,566 in stock By Investing.com - Investing.com Canada
Finanzdaten der Immunome Inc-Aktie (IMNM)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immunome Inc-Aktie (IMNM) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BIENAIME JEAN JACQUES | Director |
Mar 25 '25 |
Buy |
7.78 |
7,800 |
60,684 |
31,415 |
| SIEGALL CLAY B | President and CEO |
Mar 26 '25 |
Buy |
7.29 |
137,100 |
999,459 |
806,736 |
| BIENAIME JEAN JACQUES | Director |
Mar 24 '25 |
Buy |
8.21 |
7,000 |
57,470 |
23,615 |
| Tsai Philip | Chief Technology Officer |
Mar 24 '25 |
Buy |
8.42 |
12,300 |
103,566 |
33,300 |
| SIEGALL CLAY B | President and CEO |
Jan 31 '25 |
Buy |
7.75 |
150,000 |
1,162,500 |
669,636 |
| SIEGALL CLAY B | President and CEO |
Nov 21 '24 |
Buy |
9.54 |
66,057 |
630,263 |
485,693 |
| SIEGALL CLAY B | President and CEO |
Nov 22 '24 |
Buy |
9.78 |
33,943 |
331,918 |
519,636 |
| Lechleider Robert | Chief Medical Officer |
Nov 21 '24 |
Buy |
9.48 |
15,805 |
149,800 |
15,805 |
| Tsai Philip | Chief Technology Officer |
Nov 21 '24 |
Buy |
9.43 |
21,000 |
198,030 |
21,000 |
| Rosett Max | Chief Financial Officer |
Sep 19 '24 |
Option Exercise |
1.05 |
42,000 |
44,100 |
61,856 |
0.01%
2.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):